Dr Brijesh Patel graduated with distinction honours from University College London Medical School where he was also awarded a Sir Edward Meyerstein Foundation Scholarship for best aggregate performance during basic medical sciences (years 1 and 2). He initially trained in general internal medicine at the former Royal Postgraduate Medical School (Hammersmith Hospital) attaining MRCP during this time. He subsequently pursued clinical training in Anaesthesia and Intensive Care Medicine, through Guy’s and St Thomas’ Hospitals.
He was appointed as one of the first NIHR ‘Walport’ Academic Clinical Fellows within the Imperial School of Anaesthesia. During this time he successfully attained a prestigious Wellcome Trust Clinical Research Training Fellowship to undertake a PhD within the department at Imperial College London. His PhD investigated the role of tumour necrosis factor (TNF), long implicated in lung injury pathogenesis, and discovered that TNF-signalling triggers alveolar epithelial dysfunction in experimental lung injury through activation of death signals. He held the prestigious Gold Medal for Research from the Intensive Care Society (UK) in 2011/12 for research undertaken during his PhD studies. He was also awarded institutional and regional prizes for his research. Having completed his PhD, he went on to complete advanced training in Intensive Care Medicine through the Royal Brompton and King’s College Hospitals. In 2014, he was appointed as a NIHR Clinical Lecturer in Anaesthesia and Intensive Care.
He is as an honorary consultant at the Royal Brompton & Harefield adult intensive care units. He has clinical interests in cardiothoracic intensive care and application of extracorporeal life support (ECLS) technologies. He is a member of the ECLS team at Royal Brompton hospital where he leads the ICU research programme.
His current research focuses on the pathophysiology and basic mechanisms of cell death induced organ injury and inflammation within critical care disease states, including ARDS, sepsis and burns. He has particular interests in the optimisation and improvement of translational disease models of critical illness. He is chief investigator of a number of studies examining physiology-based ventilation algorithms to personalise mechanical ventilation during weaning and during the application of adjunctive interventions in ARDS.
He is the an associate editor for the Journal of the Intenisve Care Society (JICS) and chairperson for the research subcommittee for the commisioned UK ECMO network for adults with sever respiratory failure.
He has been funded by the European Commision Horizon 2020 funding scheme, Academy of Medical Sciences (UK), the National Institute of Academic Anaesthesia, the European Society of Intensive Care Medicine and industry.
- Cell death and survival mechanisms within the lung, in particular, in ARDS and primary graft dysfunction post-lung transplantation.
- Physiological and biological personalisation for ARDS management.
- Cell death mechanisms during ICU acquired muscle wasting.
- Mechanisms of failure to wean from mechanical ventilation.
- Inflammation and coagulation during extra-corporeal life support.
et al., 2022, Towards a biological definition of ARDS: are treatable traits the solution?, Intensive Care Medicine Experimental, Vol:10, ISSN:2197-425X, Pages:1-14
et al., 2022, PAciFy Cough-a multicentre, double-blind, placebo-controlled, crossover trial of morphine sulphate for the treatment of pulmonary Fibrosis Cough, Trials, Vol:23, ISSN:1745-6215
et al., 2022, Decision support system to evaluate ventilation in the acute respiratory distress syndrome (DeVENT study)-trial protocol, Trials, Vol:23, ISSN:1745-6215, Pages:1-18
et al., 2022, RAND appropriateness panel to determine the applicability of international guidelines on the management of acute respiratory distress syndrome (ARDS) and other strategies in the context of the COVID-19 pandemic, Thorax, Vol:77, ISSN:0040-6376, Pages:129-135